Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Payables (2021 - 2025)

Valion Bio has reported Payables over the past 5 years, most recently at $264000.0 for Q4 2025.

  • For Q4 2025, Payables rose 111.2% year-over-year to $264000.0; the TTM value through Dec 2025 reached $264000.0, up 111.2%, while the annual FY2025 figure was $264000.0, 111.2% up from the prior year.
  • Payables for Q4 2025 was $264000.0 at Valion Bio, down from $465000.0 in the prior quarter.
  • Over five years, Payables peaked at $1.9 million in Q2 2022 and troughed at $125000.0 in Q4 2024.
  • A 5-year average of $754823.5 and a median of $625000.0 in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: soared 124.71% in 2022 and later plummeted 82.47% in 2024.
  • Year by year, Payables stood at $789000.0 in 2021, then soared by 124.71% to $1.8 million in 2022, then plummeted by 59.79% to $713000.0 in 2023, then plummeted by 82.47% to $125000.0 in 2024, then skyrocketed by 111.2% to $264000.0 in 2025.
  • Business Quant data shows Payables for TIVC at $264000.0 in Q4 2025, $465000.0 in Q3 2025, and $234000.0 in Q2 2025.